The product of peripheral blood platelet and serum C-reactive protein (P-CRP) sensitively and accurately predicts the prognosis of malignant tumors by fully combining the characteristics of PLT and CRP elevation that result in a poor cancer prognosis.[6–9]. This evidence concerns the gene CRP and cancer.